SBL
KLDO

Sargent Bickham Lagudis’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Sargent Bickham Lagudis’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100
Closed -$1K – 1031
2021
Q1 		$1K Hold
100
– – ﹤0.01% 925
2020
Q4 		$1K Hold
100
– – ﹤0.01% 861
2020
Q3 		$1K Buy
+100
New +$693 ﹤0.01% 780

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sargent Bickham Lagudis's KLDO Position: Q2 2021 in Review

Sargent Bickham Lagudis sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2021, closing a stake of 100 shares — an estimated $1K sold.

Sargent Bickham Lagudis first reported a position in KLDO in Q3 2020 and held it in 3 quarters. The position peaked at $1K in Q1 2021. 71 funds tracked by Wall St. Rank hold KLDO as of Q2 2021.

  • Sargent Bickham Lagudis reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 100 Kaleido Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $1K.
  • Sargent Bickham Lagudis first reported a position in Kaleido Biosciences, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Sargent Bickham Lagudis's Kaleido Biosciences, Inc. Common Stock position peaked at $1K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q2 2021, filed 19 Jul 2021.